Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders

Neuropsychopharmacology

Volumn 25, Issue 6, 2001, Pages 904-914

  Kalkman, Hans Otto ^a   Subramanian, Natarajan ^a   Hoyer, Daniel ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adrenergic receptors; Dopamine receptors; Iloperidone; Psychotic disorders; Receptor binding profile; Serotonin receptors

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HISTAMINE H1 RECEPTOR; ILOPERIDONE; MUSCARINIC RECEPTOR; RADIOLIGAND; RECEPTOR SUBTYPE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CATTLE; CELL STRAIN; CHEMICAL STRUCTURE; CHO CELL; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DEPRESSION; DRUG BINDING; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; GUINEA PIG; HELA CELL; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CATTLE; CHO CELLS; CLOZAPINE; CRICETINAE; DOPAMINE AGONISTS; GUINEA PIGS; HUMANS; ISOXAZOLES; MALE; MEMBRANES; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE; RECEPTORS, HISTAMINE H1; RECEPTORS, MUSCARINIC; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS;

EID: 0035673012     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00285-8     Document Type: Article

References (69)

1. Antipsychotic-induced weight gain: A comprehensive research synthesis
2. Phencyclidine-induced deficits in prepulse inhibition are blocked by prazosin, an α-1 noradrenergic antagonist
3. Clozapine - A novel antipsychotic agent
4. Do central antiadrenergic actions contribute to the atypical properties of clozapine?
5. Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long-term dyskinesia reduction
6. 6 receptor antagonist, Ro 04-6790, in rats
7. α2C-Adrenoceptor-overexpressing mice are impaired in executing nonspatial and spatial escape
8. Alpha2C-adrenoceptor overexpression disrupts execution of spatial and non-spatial search patterns
9. Efficacy of 4 mg/day and 8 mg/day iloperidone (HP 873) administered to schizophrenic patients for 42 days
10. 2 receptor mRNA
11. Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular diesease
12. 1D binding sites in various species: Similar pharmacological profile in dog, monkey, calf, guinea-pig and human brain membranes
13. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia
14. 2-adrenergic receptors
15. 50) of an enzymatic reaction
16. Studies to assess if pizotifen improves migraine beyond the benefit offered by acute sumatriptan alone
17. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response
18. Effects of atypical antipsychotic agents on social behavior in rodents
19. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
20. A bridging study of iloperidone in schizophrenic inpatients
21. Iloperidone (HP 873): A study of safety and tolerance in schizophrenic inpatients
22. Dopamine in schizophrenia: A review and reconceptualization
23. Hypothalamic neuronal histamine regulates feeding circadian rhythm in rats
24. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression
25. A role for 5-HT2C receptor antagonists in the treatment of Parkinson's disease?
26. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: Investigative and therapeutic perspectives
27. 6 serotonin receptors may reflect psychoactive profile
28. Serotonin (2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
29. Prazosin modulates firing pattern of dopamine neurons in rat ventral tegmental area
30. Adrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys
31. 2 receptor binding in patients with chronic schizophrenia
32. 2-Adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinson actions of L-Dopa in the MPTP-lesioned primate model of Parkinson's disease
33. 2 adrenoceptor blockade
34. Molecular approaches to receptors as targets for drug discovery
35. 7 receptors expressed in insect cells using the baculovirus system
36. 2-adrenoceptor antagonists in mice
37. A point mutation (D79N) of the alpha2A adrenergic receptor abolishes the antiepileptogenic action of endogenous norepinephrine
38. 2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
39. 2B receptor antagonist with anxiolytic properties
40. 2C receptor antagonist
41. Iloperidone binding to human and rat dopamine and 5-HT receptors
42. The effects of a selective D4 dopamine receptor antagonist (L-745, 870) in acutely psychotic inpatients with schizophrenia
43. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine
44. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
45. 3 receptors
46. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin pKi values
47. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study
48. 2A receptor blockade
49. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double blind PET study of schizophrenic patients
50. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?
51. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the Nucleus Accumbens and Striatum
52. Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients
53. 2C receptor antagonist
54. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
55. 2-adrenoceptor subtype C in mice affects the development of behavioral despair and stress-induced increase in plasma corticosterone levels
56. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
57. Antipsychotic drug doses and neuroleptic/dopamine receptors
58. Novel dopamine receptors half a decade later
59. 2 antagonists with potential atypical antipsychotic activity: Antipsychotic profile of iloperidone (HP 873)
60. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent
61. Refractory schizophrenia and atypical antipsychotics
62. 2A antagonist fananserin in the treatment of schizophrenia
63. 2 receptors
64. 4 receptor with high affinity for the antipsychotic clozapine
65. Psilocybin induces schizophrenia-like psychosis in human via a serotonin-2 agonist action
66. 11C]raclopride
67. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials
68. The dopamine hypothesis of schizophrenia: Current status, future prospects